Erratum. GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. Diabetes 2019;68:

Zhang, Yanqing; Parajuli, Keshab Raj; Fava, Genevieve E; Gupta, Rajesh; Xu, Wei; Nguyen, Lauren U.; Zakaria, Anadil F.; Fonseca, Vivian; Wang, Hongjun; Mauvais-Jarvis, Franck; Sloop, Kyle W.; Wu, Hongju

doi:10.2337/db20-er02c

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The a-yellow fluorescence protein (aYFP) mice (males and females) were generated and genotyped in-house as described 34 . Briefly, the glucagon-cre mice, B6.Cg-Tg(Gcg-cre)1Herr/Mmnc (Identification# 358-UNC, the Mutant Mouse Regional Resource Centers), were bred with Rosa26-YFP-LoxP mice (The Jackson Laboratory, Bar Harbor, ME, USA).…”

Section: Materials and Methods Animalsmentioning

confidence: 99%

“…In the current study, we investigated whether Pax4 gene delivery was able to induce a-to-b cell conversion in primary islets. To accomplish this, we performed lineage-tracing analysis using isolated islets from aYFP mice in which pancreatic a cells were labeled by enhanced yellow fluorescence protein (YFP) 34 . Immunofluorescence staining confirmed efficient and specific YFP-labeling of pre-existing a cells in the pancreas of aYFP mice (Fig.…”

Section: Pax4 Gene Delivery Induces A-to-b Cell Transdifferentiation In Primary Mouse Isletsmentioning

confidence: 99%

“…Also, it should be noted that in STZ-induced T1D models, glucagon levels are in general high compared with normal mice, which is largely contributable to the loss of paracrine insulin suppression of glucagon secretion. Of note, in normal mice, the nonfasting glucagon level is usually 100 to 150 pg/ml 34 . Furthermore, we examined islet grafts in the liver at the end of the transplantation study.…”

Section: Pax4 Gene Delivery Into Mouse Islets Improves the Therapeutic Efficacy Of Islet Transplantationmentioning

confidence: 99%

See 2 more Smart Citations

Pax4 Gene Delivery Improves Islet Transplantation Efficacy by Promoting β Cell Survival and α-to-β Cell Transdifferentiation

et al. 2020

Self Cite

View full text Add to dashboard Cite

The transcription factor Pax4 plays an essential role in the development of insulin-producing β cells in pancreatic islets. Ectopic Pax4 expression not only promotes β cell survival but also induces α-to-β cell transdifferentiation. This dual functionality of Pax4 makes it an appealing therapeutic target for the treatment of insulin-deficient type 1 diabetes (T1D). In this study, we demonstrated that Pax4 gene delivery by an adenoviral vector, Ad5.Pax4, improved β cell function of mouse and human islets by promoting islet cell survival and α-to-β cell transdifferentiation, as assessed by multiple viability assays and lineage-tracing analysis. We then explored the therapeutic benefits of Pax4 gene delivery in the context of islet transplantation using T1D mouse models. Both mouse-to-mouse and human-to-mouse islet transplantation, via either kidney capsule or portal vein, were examined. In all settings, Ad5.Pax4-treated donor islets (mouse or human) showed substantially better therapeutic outcomes. These results suggest that Pax4 gene delivery into donor islets may be considered as an adjunct therapy for islet transplantation, which can either improve the therapeutic outcome of islet transplantation using the same amount of donor islets or allow the use of fewer donor islets to achieve normoglycemia.

show abstract

Section: Materials and Methods Animalsmentioning

confidence: 99%

Section: Pax4 Gene Delivery Induces A-to-b Cell Transdifferentiation In Primary Mouse Isletsmentioning

confidence: 99%

Section: Pax4 Gene Delivery Into Mouse Islets Improves the Therapeutic Efficacy Of Islet Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Pax4 Gene Delivery Improves Islet Transplantation Efficacy by Promoting β Cell Survival and α-to-β Cell Transdifferentiation

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Higher or inappropriately normal levels of GIP are detected in T2D patients also during the fast, and the fine regulation of insulin and glucagon release in response to different glycemic levels is problematic. On the other side, GLP-1 response is preserved in T2D, but GLP-1 secretion in response to meal consumption weakens over time, making GLP-1-based therapy an effective strategy to manage hyperglycemia as replacement therapy ( 7 , 13 , 14 ).…”

Section: Gip and Glp-1: An Overviewmentioning

confidence: 99%

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis

Lisco

Tullio²,

Disoteo³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

Tirzepatide, a dual agonist of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide 1 (GLP-1) receptors, improved glucose control and reduced body weight in different therapeutic approaches. Herein, we overviewed the role of GIP and GLP-1 in the pathophysiology of type 2 diabetes and systematically reviewed the efficacy and safety of injectable incretin-based therapy added to basal insulin in light of the results of the SURPASS-5 trial. We identified eleven randomized clinical trials. GLP-1 receptor agonists (GLP-1RAs) or Tirzepatide added to basal insulin than rigorously titrated basal insulin significantly ameliorates glucose control (Δ HbA1c = -1%, 95% CI -1.25; -0.74, I2 94%; Δ FPG = -14.6 mg/dL, 95% CI -21.6-; -7.6, I2 90%; chance to achieve HbA1c <7% = RR 2.62, 95% CI 2.10; 3.26, I2 89%), reduces body weight (Δ = -3.95 kg, 95% CI -5.1, -2.79, I2 96%) without increasing the risk of hypoglycemia (RR = 1.01, 95% CI 0.86; 1.18, I2 7.7%). Tirzepatide provides an impressive weight loss exceeding that observed with GLP-1RAs. Injectable incretin-based therapy plus basal insulin remains a potent and safe therapeutic approach in uncontrolled type 2 diabetes patients previously treated with basal insulin alone. Tirzepatide is expected to ameliorate the management of “diabesity” in this usually difficult-to-treat cluster of patients.

show abstract

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

Zheng,

Zong,

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types within the human body. This receptor specifically interacts with GLP-1, a key hormone that plays an integral role in regulating blood glucose levels, lipid metabolism, and several other crucial biological functions. In recent years, GLP-1 medications have become a focal point in the medical community due to their innovative treatment mechanisms, significant therapeutic efficacy, and broad development prospects. This article thoroughly traces the developmental milestones of GLP-1 drugs, from their initial discovery to their clinical application, detailing the evolution of diverse GLP-1 medications along with their distinct pharmacological properties. Additionally, this paper explores the potential applications of GLP-1 receptor agonists (GLP-1RAs) in fields such as neuroprotection, anti-infection measures, the reduction of various types of inflammation, and the enhancement of cardiovascular function. It provides an in-depth assessment of the effectiveness of GLP-1RAs across multiple body systems-including the nervous, cardiovascular, musculoskeletal, and digestive systems. This includes integrating the latest clinical trial data and delving into potential signaling pathways and pharmacological mechanisms. The primary goal of this article is to emphasize the extensive benefits of using GLP-1RAs in treating a broad spectrum of diseases, such as obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer. The ongoing development of new indications for GLP-1 drugs offers promising prospects for further expanding therapeutic interventions, showcasing their significant potential in the medical field.

show abstract

Erratum. GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. Diabetes 2019;68:

Cited by 3 publications

References 0 publications

Pax4 Gene Delivery Improves Islet Transplantation Efficacy by Promoting β Cell Survival and α-to-β Cell Transdifferentiation

Pax4 Gene Delivery Improves Islet Transplantation Efficacy by Promoting β Cell Survival and α-to-β Cell Transdifferentiation

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

Contact Info

Product

Resources

About